Spectrum Pharmaceuticals
Trial Pipeline
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects
NCT04436562
Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb
NCT01560884
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT00865969
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
NCT00656786
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
NCT00613691
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
NCT00598806
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
NCT00495079
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
NCT00427219
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
NCT00005887
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 2 |
What the Pipeline for Spectrum Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, Spectrum Pharmaceuticals is linked to 10 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 10% of the sponsor's indexed portfolio — and 9 are already marked complete, representing roughly 90% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Spectrum Pharmaceuticals reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Spectrum Pharmaceuticals is Phosphate Binding Capacity with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.